Literature DB >> 8479739

Mutation of a phosphorylation site in the DNA-binding domain is required for redox-independent transactivation of AP1-dependent genes by v-Jun.

T Oehler1, A Pintzas, S Stumm, A Darling, D Gillespie, P Angel.   

Abstract

The ability of the nuclear oncoprotein Jun to activate transcription is controlled both by level of DNA binding and by the activity of its transactivation domain. Control of DNA binding is achieved by two mechanisms: phosphorylation and redox regulation. Mutation of Ser-226 inhibits phosphorylation of the DNA binding, resulting in enhanced DNA-binding and transactivation activity of Jun. In contrast, mutation of Cys-252, which is the target for repression of DNA-binding activity under oxidative conditions, results in a strong decrease of Jun-specific activation of transcription. However, transactivation by c-Jun-Cys-252 is fully restored upon mutation of Ser-226. Both mutations are also found in the oncogenic counterpart of c-Jun, v-Jun, and are the only differences between these proteins in the DNA-binding domain, suggesting that v-Jun escapes down-modulation of DNA binding by both mechanisms. However, inhibition of phosphorylation of Ser-226 is absolutely required for the ability of v-Jun to activate transcription of AP-1-dependent genes in a redox-independent manner.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8479739

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  2 in total

1.  Activation of c-Jun transcription factor by substitution of a charged residue in its N-terminal domain.

Authors:  W K Hoeffler; A D Levinson; E A Bauer
Journal:  Nucleic Acids Res       Date:  1994-04-11       Impact factor: 16.971

2.  Identification of residues in the human DNA repair enzyme HAP1 (Ref-1) that are essential for redox regulation of Jun DNA binding.

Authors:  L J Walker; C N Robson; E Black; D Gillespie; I D Hickson
Journal:  Mol Cell Biol       Date:  1993-09       Impact factor: 4.272

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.